Jefferies International issued a report on UDG Healthcare PLC (LON:UDG), stepping up its target to 720.00GBX earlier today
- Updated: October 1, 2016
Jefferies International bumped up the stock price target of UDG Healthcare PLC (LON:UDG) to 720.00GBX indicating a possible upside of 0%.
Previously on 9/28/2016, Stifel reported on UDG Healthcare PLC (LON:UDG) raised the target price from 0.00GBX to 620.00GBX. At the time, this indicated a possible downside of -0.02%.
Yesterday UDG Healthcare PLC (LON:UDG) traded 1.34% higher at 0.00GBX. The company’s 50-day moving average is 627.69GBX and its 200-day moving average is 600.67GBX. The last closing price is down 6.71% from the 200-day moving average, compared to the S&P 500 which has decreased -0.01% over the same time. 726,704 shares of the stock were exchanged, up from an average trading volume of 499,487
See Chart Below
UDG Healthcare PLC has a 52 week low of 452.20GBX and a 52 week high of 656.50GBX with a P/E ratio of 21.73 The company’s market cap is currently 0 GBX.
In addition to Jefferies International reporting its target price, a total of 6 brokers have issued a report on the stock. The consensus target price is 9.00GBX with 1 broker rating the stock a strong buy, 6 brokers rating the stock a buy, 1 broker rating the stock a hold, 0 brokers rating the stock a underperform, and finally 0 brokers rating the stock a sell.
General Information About UDG Healthcare PLC (LON:UDG)
UDG Healthcare plc, formerly United Drug plc, is a healthcare services provider in the Republic of Ireland, the United Kingdom, North America and Continental Europe. The Company operates in three segments. The Ashfield Commercial & Medical Services segment is engaged in the provision of sales, marketing and healthcare communications services to pharmaceutical companies, and it also provides sales teams, healthcare communications, telesales, nurse educators, medical information, pharmacovigilance, regulatory and event management services to over 300 healthcare companies in approximately 20 countries. The Sharp Packaging Services segment is engaged in contract packaging and clinical trial packaging services for the pharmaceutical and biotechnology industries, and also provides Track and Trace serialization services. The Supply Chain Services segment includes Aquilant, a provider of outsourced sales, marketing, distribution and engineering services to the medical and scientific sectors.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.